Cytosorbents Corp (CTSO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on July 24, 2020. The report details the completion of a previously announced underwritten public offering of common stock.
Key Financial Metrics
- Gross Proceeds: Approximately $57.5 million.
- Shares Issued: 6,052,631 shares of Common Stock.
- Underwriting Discounts and Expenses: The filing states gross proceeds are before deducting underwriting discounts, commissions, and fees; specific net proceeds are not provided in this text.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: This filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios.
Material Changes
The primary material event is the capital raise via the public offering. The underwriters exercised their option in full to purchase an additional 789,473 shares, bringing the total shares sold to 6,052,631. This transaction significantly increased the company's cash position relative to the pre-offering state, though the exact post-transaction cash balance is not disclosed.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure of the offering completion. The offering was conducted pursuant to an existing shelf registration statement on Form S-3 (File No. 333-226372). Cowen and Company, LLC and SVB Leerink LLC acted as joint book-running managers, with B. Riley FBR as co-manager.
Investor Verification Checklist
- Verify the exact net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the total number of outstanding shares post-offering to assess dilution impact.
- Review the use of proceeds as detailed in the accompanying prospectus or Form S-3.
- Check for any subsequent filings regarding the deployment of the raised capital.